Fredrik Schjesvold, MD, PhD, Discusses Adjustments in the Treatment of Myeloma During the COVID-19 Pandemic

Video

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about how the COVID-19 pandemic impacted the care of multiple myeloma at the Oslo Myeloma Center .

At the 2021 International Myeloma Workshop, CancerNetwork® spoke with Fredrik Schjesvold, MD, PhD, founder and head of the Oslo Myeloma Center, about the precautions that were initially put in place at the beginning of the COVID-19 pandemic and how his facility’s strategy has evolved over time.

Transcript:

Initially, we had a study hold for some time in most studies, but we ended that quite fast after considering that myeloma is more dangerous than COVID, and we should provide the best possible treatment to our patients. Besides that, we haven't done much with our approach to the patients, except not being allowed to come in if they’re sick, using masks all the time, trying to keep the distance, [and] trying to have good hygiene…. We did see a reduction in referred patients from other hospitals. [As] we are a referral hospital, we get a lot of patients from other regions, and it seemed like that was less popular in this period—to travel to our center instead of just using their local hospital. I think that's probably understandable, but I think that’s over now. In the beginning, people were stressed, doctors were stressed, and patients were stressed. I know that many [patients with] myeloma have more or less locked themselves indoors. We also know that [patients with] myeloma do not respond as well to vaccines as others, so it’s sort of valid but you cannot live like that. [Patients] need to get on with their lives and start to behave more normal, and I think that’s what's happening now.

One interesting thing is to see [a decline] in other infections—[to see] how [many] common infections in society we can, not get rid of, but see a lot less of if hygienic measures and distance measures are taken. Whether that’s worth it is a different question, of course.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Related Content